| Remdesivir for 5 or 10 days in patients with severe Covid-19 JD Goldman, DCB Lye, DS Hui, KM Marks, R Bruno, R Montejano, ... New England Journal of Medicine 383 (19), 1827-1837, 2020 | 1710 | 2020 |
| Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial CD Spinner, RL Gottlieb, GJ Criner, JRA López, AM Cattelan, ... Jama 324 (11), 1048-1057, 2020 | 1551 | 2020 |
| Early remdesivir to prevent progression to severe Covid-19 in outpatients RL Gottlieb, CE Vaca, R Paredes, J Mera, BJ Webb, G Perez, G Oguchi, ... New England Journal of Medicine 386 (4), 305-315, 2022 | 1311 | 2022 |
| Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation FM Marty, P Ljungman, RF Chemaly, J Maertens, SS Dadwal, RF Duarte, ... New England Journal of Medicine 377 (25), 2433-2444, 2017 | 1121 | 2017 |
| Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis FM Marty, L Ostrosky-Zeichner, OA Cornely, KM Mullane, JR Perfect, ... The Lancet infectious diseases 16 (7), 828-837, 2016 | 718 | 2016 |
| Transmission of lymphocytic choriomeningitis virus by organ transplantation SA Fischer, MB Graham, MJ Kuehnert, CN Kotton, A Srinivasan, FM Marty, ... New England Journal of Medicine 354 (21), 2235-2249, 2006 | 601 | 2006 |
| Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases TJ Henrich, E Hanhauser, FM Marty, MN Sirignano, S Keating, TH Lee, ... Annals of internal medicine 161 (5), 319-327, 2014 | 515 | 2014 |
| Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants FM Marty, LA Cosimi, LR Baden New England Journal of Medicine 350 (9), 950-952, 2004 | 504 | 2004 |
| CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation FM Marty, DJ Winston, SD Rowley, E Vance, GA Papanicolaou, ... New England Journal of Medicine 369 (13), 1227-1236, 2013 | 429 | 2013 |
| Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial FM Marty, P Ljungman, GA Papanicolaou, DJ Winston, RF Chemaly, ... The Lancet infectious diseases 11 (4), 284-92, 2011 | 418 | 2011 |
| Persistent and relapsing babesiosis in immunocompromised patients PJ Krause, BE Gewurz, D Hill, FM Marty, E Vannier, IM Foppa, ... Clinical Infectious Diseases 46 (3), 370-376, 2008 | 366 | 2008 |
| Infectious complications associated with alemtuzumab use for lymphoproliferative disorders SI Martin, FM Marty, K Fiumara, SP Treon, JG Gribben, LR Baden Clinical infectious diseases 43 (1), 16-24, 2006 | 290 | 2006 |
| Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6 WW Seeley, FM Marty, TM Holmes, K Upchurch, RJ Soiffer, JH Antin, ... Neurology 69 (2), 156-165, 2007 | 289 | 2007 |
| How to obtain a nasopharyngeal swab specimen. FM Marty, K Chen, KA Verrill The New England journal of medicine 382 (22), e76-e76, 2020 | 283 | 2020 |
| Three Patients with Full Facial Transplantation B Pomahac, J Pribaz, E Eriksson, EM Bueno, JR Diaz-Siso, FJ Rybicki, ... New England Journal of Medicine 366 (8), 715-22, 2011 | 283 | 2011 |
| Diagnostic performance of the (1→ 3)-β-d-glucan assay for invasive fungal disease S Koo, JM Bryar, JH Page, LR Baden, FM Marty Clinical infectious diseases 49 (11), 1650-1659, 2009 | 282 | 2009 |
| Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and … FM Marty, WW Yeh, CB Wennersten, L Venkataraman, E Albano, ... Journal of clinical microbiology 44 (2), 595-597, 2006 | 263 | 2006 |
| Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial RK Avery, S Alain, BD Alexander, EA Blumberg, RF Chemaly, ... Clinical Infectious Diseases 75 (4), 690-701, 2022 | 233 | 2022 |
| Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study GA Papanicolaou, FP Silveira, AA Langston, MR Pereira, RK Avery, ... Clinical Infectious Diseases 68 (8), 1255-1264, 2019 | 227 | 2019 |
| Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis CH Feldman, LT Hiraki, WC Winkelmayer, FM Marty, JM Franklin, SC Kim, ... Arthritis & rheumatology 67 (6), 1577-1585, 2015 | 225 | 2015 |
